Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients.
Anemia and erythrocytosis (PTE) are common after kidney transplantation. We sought to determine the influence of sirolimus compared to mycophenolate mofetil (MMF) on post-transplant erythropoiesis. A total of 214 patients with recent kidney or kidney-pancreas transplants were treated with either sirolimus-based (n = 87) or MMF-based (n = 127) therapy. At 12 months, the prevalence of anemia was 31% with MMF and 57% with sirolimus (p < 0.001). Linear regression was used to examine the independent influence of sirolimus on hemoglobin at 12 months, controlling for multiple factors including gender and renal function. Sirolimus remained a significant correlate of lower hemoglobin in all patients (slope =-1.060, 95% CI: -1.76 to -0.362, p = 0.003), and in patients without PTE (slope =-0.671, 95% CI: -1.32 to -0.028, p = 0.041). PTE, defined as a persistent hematocrit above 51%, occurred in 19% with MMF and 7% with sirolimus (p = 0.013). PTE was examined using logistic regression analysis. Sirolimus use correlated negatively with PTE (odds ratio with sirolimus = 0.33, 95% CI: 0.12 to 0.89, p = 0.028). Our results indicate that, compared to treatment with MMF, treatment of kidney or kidney-pancreas recipients with sirolimus is associated with a higher prevalence of anemia, lower hemoglobin levels and lower incidence of PTE.
Augustine
Joshua J
JJ
Department of Nephrology, Case Western University Hospitals, Cleveland, OH, USA. joshua.augustine@uhhs.com
Knauss
Thomas C
TC
Schulak
James A
JA
Bodziak
Kenneth A
KA
Siegel
Christopher
C
Hricik
Donald E
DE
D000740:Anemia / Q000209:etiology* / Q000517:prevention & control; D004920:Erythropoiesis / Q000187:drug effects*; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000502:physiology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D044469:Racial Groups; D014019:Tissue Donors
D006454:Hemoglobins; D007166:Immunosuppressive Agents